The effects of lobeline on α4β2* nicotinic acetylcholine receptor binding and uptake of [18F]nifene in rats

Journal of Neuroscience Methods

Volumn 214, Issue 2, 2013, Pages 163-169

  Hillmer, Ansel T ^a,b   Wooten, Dustin W ^a,b   Farhoud, Mohammed ^c   Barnhart, Todd E ^a   Mukherjee, Jogeshwar ^d   Christian, Bradley T ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F nifene; BBB amine transporter; Lobeline; Nicotinic acetylcholine receptor; PET; Smoking cessation

Indexed keywords

FLUORINE 18; LOBELINE; NICOTINE; NICOTINIC RECEPTOR ALPHA4BETA2; NIFENE F 18; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN BLOOD FLOW; CEREBELLUM; CONTROLLED STUDY; FEMALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SMOKING CESSATION; THALAMUS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; LOBELINE; NICOTINIC AGONISTS; PROTEIN BINDING; PYRIDINES; PYRROLES; RATS; RECEPTORS, NICOTINIC;

EID: 84874416150     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2013.01.018     Document Type: Article

References (33)

1. Albuquerque E.X., Pereira E.F., Alkondon M., Rogers S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009, 89:73-120.
2. Allen D.D., Lockman P.R., Roder K.E., Dwoskin L.P., Crooks P.A. Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J Pharmacol Exp Ther 2003, 304:1268-1274.
3. Bhat R.V., Turner S.L., Selvaag S.R., Marks M.J., Collins A.C. Regulation of brain nicotinic receptors by chronic agonist infusion. J Neurochem 1991, 56:1932-1939.
4. Brioni J.D., Decker M.W., Sullivan J.P., Arneric S.P. The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv Pharmacol 1996, 37:153-214.
5. Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., et al. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006, 63:907-915.
6. Burghaus L., Schütz U., Krempel U., Lindstrom J., Schröder H. Loss of nicotinic acetylcholine receptor subunits α4 and α7 in the cerebral cortex of parkinson patients. Parkinsonism Relat Disord 2003, 9:243-246.
7. Christian B.T., Vandehey N.T., Floberg J.M., Mistretta C.A. Dynamic PET denoising with HYPR processing. J Nucl Med 2010, 51:1147-1154.
8. Constantinescu C.C., Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol 2009, 54:2885-2899.
9. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 2001, 49:175-184.
10. Damaj M.I., Patrick G.S., Creasy K.R., Martin B.R. Pharmacology of lobeline, a nicotinic receptor ligand. J Pharmacol Exp Ther 1997, 282:410-419.
11. Deuther-Conrad W., Patt J.T., Lockman P.R., Allen D.D., Patt M., Schildan A., et al. Norchloro-fluoro-homoepibatidine (NCFHEB) - a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur Neuropsychopharmacol 2008, 18:222-229.
12. Diamond I. Choline metabolism in brain. The role of choline transport and the effects of phenobarbital. Arch Neruol 1971, 24:333-339.
13. Dischino D., Welch M.J., Kilborun M.R., Raichle M.E. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 1983, 24:1030-1038.
14. 3H]cytisine. Neuroscience 1994, 62:929-944.
15. Hillmer A.T., Wooten D.W., Moirano J.M., Slesarev M., Barnhart T.E., Engle J.W., et al. Specific α4β2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. Synapse 2011, 65:1309-1318.
16. 18F-nifene kinetics in the nonhuman primate. J Nucl Med 2012, 53:1471-1480.
17. Horti A., Scheffel U., Stathis M., Finley P., Ravert H.T., London E.D., et al. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J Nucl Med 1997, 38:1260-1265.
18. Houlihan L.M., Slater Y., Duerra D.L., Peng J-H., Kuo Y-P., Lukas R.J., et al. Activity of cytisine and its brominated isosteres on recombinant human α7, α4β2 and α4β4 nicotinic acetylcholine receptors. J Neurochem 2001, 78:1029-1043.
19. 18F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging. EJNMMI Res 2011, 1:1-9.
20. 11C]A-84543: an enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. Pharmacol Lett 1998, 63:13-18.
21. Kessler R.M., Ansari M.S., de Paulis T., Schmidt D.E., Clanton J.A., Smith H.E., et al. High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. J Nucl Med 1991, 32:1593-1600.
22. 11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 1994, 14:995-1010.
23. Miller D.K., Crooks P.A., Zheng G., Grinevich V.P., Norrholm S.D., Dwoskin L.P. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther 2004, 310:1035-1045.
24. Miller D.K., Lever J.R., Rodvelt K.R., Baskett J.A., Will M.J., Lobeline K.G.R. a potential pharmacotherapy for drug addiction, binds to (-opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend 2007, 89:282-291.
25. Muzic R.F., Cornelius S. COMKAT: compartment model kinetic analysis tool. J Nucl Med 2001, 42:636-645.
26. Parker M.J., Beck A.V., Luetje C.W. Neuronal nicotinic receptor β2 and β4 subunits confer large differences in agonist binding affinity. Mol Pharm 1998, 54:1132-1139.
27. Paxinos G., Watson C. The rat brain in sterotaxic coordinates 1998, Academic Press, San Diego. 4th ed.
28. 18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol 2006, 33:295-304.
29. Poirier M-F., Canceil O., Baylé F., Millet B., Bourdel M-C., Moatti C., et al. Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol 2002, 26:529-537.
30. Riganti L., Matteoni C., Di Angelantonio S., Mistri A., Gaimarri A., Sparatore F., et al. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells. Br J Pharmacol 2005, 146:1096-1109.
31. 3H]dopamine uptake. J Pharmacol Exp Ther 1997, 280:1432-1444.
32. 18F]F-A-85380. NeuroImage 2007, 34:1352-1362.
33. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 5:376-389.